https://doi.org/10.1016/s2468-1253(20)30007-8
B
Bingyu Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
677
Citations
4
h-index
1
i10-index
Bingyu Li is an academic researcher from Shanghai Medical College of Fudan University. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 4, co-authored 9 publications.
ORCID: 0000-0002-1007-7621Papers by this author
worksThe global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
2020 · The Lancet. Gastroenterology & hepatology · 635 citations
<scp><i>TP53</i></scp> disruptive mutation predicts platinum‐based chemotherapy and <scp>PD‐1</scp>/<scp>PD‐L1</scp> blockade response in urothelial carcinoma
2024 · The Journal of Pathology · 9 citations
https://doi.org/10.1002/path.6266
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
2024 · Cancer Immunology Immunotherapy · 8 citations
https://doi.org/10.1007/s00262-024-03651-3
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer
2023 · Urologic Oncology Seminars and Original Investigations · 4 citations
https://doi.org/10.1016/j.urolonc.2023.07.006
Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene <i>KDM6A</i> mutation
2023 · BMJ Oncology · 3 citations
https://doi.org/10.1136/bmjonc-2023-000199
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat